AVROBIO

$10.78
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
-$0.22 (-2.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AVROBIO and other stocks, options, and ETFs commission-free!

About AVRO

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA. The listed name for AVRO is AVROBIO, Inc. Common Stock.

CEO
Geoff MacKay
Employees
—
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
459.69M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.42M
High Today
$11.16
Low Today
$10.59
Open Price
$10.99
Volume
877.07K
52 Week High
$23.50
52 Week Low
$9.76

AVRO Earnings

-$1.01
-$0.67
-$0.34
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, Pre-Market

You May Also Like

BLUWW
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure